The safety and efficacy of antithyroid drugs

Expert Opinion on Drug Safety

Volumn 5, Issue 1, 2006, Pages 107-116

  Azizi, Feredioun ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antithyroid drug; Methimazole; Propylthiouracil; Thyrotoxicosis

Indexed keywords

ANTITHYROID AGENT; LEVOTHYROXINE; LIOTHYRONINE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE; THIONAMIDE DERIVATIVE; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE;

AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTHRALGIA; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GOITER; GRAVES DISEASE; HAIR DISEASE; HUMAN; HYPERTHYROIDISM; HYPOGLYCEMIA; HYPOPROTHROMBINEMIA; KIDNEY FAILURE; LIVER TOXICITY; LUNG DISEASE; LYMPHADENOPATHY; NAUSEA; POLYARTHRITIS; PREGNANCY; PSYCHOSIS; REVIEW; SALIVARY GLAND DISEASE; SIALOADENITIS; SKIN MANIFESTATION; SKIN ULCER; SMELLING DISORDER; TASTE DISORDER; THROMBOCYTOPENIA; THYROTOXICOSIS; VASCULITIS;

ADOLESCENT; ADULT; AGE FACTORS; ANTITHYROID AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAVES DISEASE; HUMANS; MALE; METHIMAZOLE; PREGNANCY; PREGNANCY COMPLICATIONS; PROPYLTHIOURACIL;

EID: 30344441486     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.1.107     Document Type: Review

References (113)

1. WARTOFSKY L, GLINOER D, SOLOMON B et al.: Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid (1991) 1:129-135.
2. ROMALDINI JH: Case selection and restrictions recommended to patients with hyperthyroidism in South America. Thyroid (1997) 7:225-228.
3. COOPER DS: Anithyroid drugs. N. Engl. J. Med (2005) 352:905-917.
4. DAVIS TF, REED LARSEN P: Thyrotoxicosis. In: Reed Larsen P et al., Eds. Williams Textbook of Endocrinology. 10th Edn, Philadelphia, Saunders (2003):393-403.
5. WU SY, SHYH TP, CHOPRA I et al.: Comparison of sodium ipodate (Oragrafin) and propylthiouracil in early treatment of hyperthyroidism. J. Clin. Endocrinol. Metab. (1982) 54:630-364.
6. WILLIAMS DF, CHOPRA IJ, ORGIAZZI J et al.: Acute effects of corticosteroids on thyroid activity in Graves' disease. J. Clin. Endocrinol. Metab. (1975) 41:354-361.
7. ASTWOOD EB, SULLIVAN J, BISSELL A et al.: Action of certain sulfornamides and of thourea upon the function of the thyroid gland of the rat. Endocrinology (1943) 32:210.
8. MAECHANT B, ALEXADER WD, ROBERTSON JWK et al.: Concentration of 35S-propylthiouracil by the thyroid gland and its relationship to anion trapping mechanism. Metabolism (1971) 20:989-999.
9. DAVIDSON B, SOODAJ KM, NEARY JT et al.: The irreversible inactivation of thyroid peroxidase by methylmercaptoimidazole, thiouracil, and propylthiouracil in vitro and its relationship to in vivo findings. Endocrinology (1978) 103:871-882.
10. LAURBERG P, WEEKE J: Dynamics of inhibition of iodothyronine deiodination during propylthiouracil treatment of thyrotoxicosis. Horm. Metab. Res. (1981) 13:289-292.
11. VOLPE R: The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr. Pharm. Des. (2001) 7:451-460.
12. MCGREGOR AM, PETERSEN MM, McLACHLAN SM et al.: Carbimazole and the autoimmune response in Graves' disease. N. Engl. J. Med. (1980) 303:302-307.
13. SONNET E, MASSART C, GIBASSIER J et al.: Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease. J. Endocrinol. Invest. (1999) 22:430-435.
14. SALVI M, GIRASOLE G, PEDRAZZONI M et al.: Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. J. Clin. Endocrinol. Metab. (1996) 81:2976-2979.
15. MITSIADES N, POULAKI V, TSELENI-BALAFOUTA S et al.: Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves' disease. Thyroid (2000) 10:527-532.
16. STASSI G, TODARO M, BUCCHIERI F et al.: Fas/Fas ligand-driven T cell apoptosis as a consequence of ineffective thyroid immunoprivilege in Hashimoto's thyroiditis. J. Immunol. (1999) 162:263-267.
17. TOTTERMAN TH, KARLSSON FA, BENGTSSON M et al.: Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease. N. Engl. J. Med. (1987) 316:15-22.
18. CORRALES JJ, LOPEZ A, CIUDAD J et al.: Methimazole therapy in Graves' disease influences the abnormal expression of CD69 (early activation antigen) on T cells. J. Endocrinol. (1997) 155:491-500.
19. WERBER RS, ROMALDINI JH, FARAH CS et al.: Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease. Thyroid (1991) 1:293-299.
20. ANDRADE VA, GROSS JL, MAIA AL: Effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study. J. Clin. Endocrinol. Metab. (2001) 86:3488-3493.
21. JORDE R, YTRE-ARNE K, STORMER J et al.: Short-term treatment of Graves' disease with methimazole in high versus low doses. J. Intern. Med. (1995) 238:161-165.
22. WILSON R, BUCHANAN L, FRASER WD et al.: A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose of carbimazole improver remission in Graves' disease? OJM (1996) 89:381-385.
23. GREBE SKG, FEEK CM, FORD HC et al.: A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole. Clin. Endocrinol. (1998) 48:585-592.
24. PASCHKE R, VOGG M, KRISTOFERITSCH R et al.: Methimazole has no dose-related effect on the intensity of the intrathyroidal autoimmune process in relapsing Graves' disease. J. Clin. Endocrinol. Metab. (1995) 80:2470-2474.
25. COOPER DS, SAXE VC, MESKELL M et al.: Acute effects of propylthiouracil (PTU) on thyroidal iodide organification and peripheral iodothyronine deiodination: correlation with serum PTU levels measured by radioimmunoassay. J. Clin. Endocrinol. Metab. (1982) 54:101-107.
26. COOPER DS, BODE HH, NATH B et al.: Methimazole pharmacology in man: studies using a newly developed radioimmunoassay for methimazole. J. Clin. Endocrinol. Metab. (1984) 58:473-479.
27. JANSSON R, DAHLBERG PA, JOHNSSON H et al.: Intrathyroidal concentrations of methimazole in patients with Graves' disease. J. Clin. Endocrinol. Metab. (1983) 57:129-132.
28. MCCRUDEN DC, HILDITCH TE, CONNELL JMC et al.: Duration of antithyroid action of methimazole estimated with an intravenous perchlorate discharge test. Clin. Endocrinol. (1987) 26:33-39.
29. MASHIO Y, BENIKO M, IKOTA A et al.: Treatment of hyperthyroidism with a small single daily dose of methimazole. Acta. Endocrinol. (1988) 119:139-144.
30. NICHOLAS WC, FISCHER RG, STEVENSON RA et al.: Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South. Med. J. (1995) 88:973-976.
31. REINWEIN D, BENKER G, LAZARUS JH et al.: A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. J. Clin. Endocrinol. Metab. (1993) 76:1516-1521.
32. PAGE SR, SHEARD CE, HERBERT M et al.: A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism. Clin. Endocrinol. (1996) 45:511-516.
33. AZIZI F: Environmental iodine intake affects the response to methimazole in patients with diffuse toxic goiter. J. Clin. Endocrinol. Metab. (1985) 61:373-377.
34. KALLNER G, VITOLS S, LJUNGGREN JG: Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease. J. Intern. Med. (1996) 239:525-529.
35. HOMSANIT M, SRIUSSADAPORN S, VANNASAENG S et al.: Efficacy of single daily dosage of methimazole versus propylthiouracil in the induction of euthyroidism. Clin. Endocrinol. (2001) 54:385-390.
36. HE CT, HSIEH AT, PEID D et al.: Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism. Clin. Endocrinol. (2004) 60:676-681.
37. KAMPMANN JP, MORTENSEN HB, BACH B et al.: Kinetics of propylthiouracil in the elderly. Acta. Med. Scand. Suppl. (1979) 624:93-98.
38. HOFFMAN WH, MICHELI JN: Pharmacokinetics of propylthiouracil in children and adolescents with Graves' disease in the hyperthyroid and euthyroid states. Dev. Pharmacol. Ther. (1988) 11:73-81.
39. JANSSON R, LINDSTROM B, DAHLBERG PA: Pharmacokinetic properties and bioavailability of methimazole. Clin. Pharmacokinet. (1985) 10:443-450.
40. COOPER DS, STEIGERWALT S, MIGDAL S: Pharmacology of propylthiouracil in thyrotoxicosis and chronic renal failure. Arch. Intern. Med. (1987) 147:785-786.
41. WEETMAN AP, RATANACHAIYAVONG S, MIDDLETON GW et al.: Prediction of outcome in Graves' disease after carbimazole treatment. Q. J. Med. (1986) 59:409-419.
42. SCHLEUSENER H, SCHWANDER J, FISCHER C et al.: Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta. Endocrinol. (1989) 120:701.
43. VITTI P, RAGO T, CHIOVATO L et al.: Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid (1997) 7:369-375.
44. BENKER G, RIENWEIN D, KAHALY G et al.: Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin. Endocrinol. (1998) 49:451-457.
45. MICHELANGELI V, POON C, TAFT J et al.: The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid (1998) 8:119-124.
46. FELDT-RASMUSSEN U, SCHLEUSENER H et al.: Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J. Clin. Endocrinol. Metab. (1994) 78:98-102.
47. FUKAO A, TAKAMATSU J, MURAKAMI Y et al.: The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves' disease. Clin. Endocrinol. (2003) 58:550-555.
48. SCHOTT M, MORGENTHALER NG, FRITZEN R et al.: Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease. Horm. Metab. Res. (2004) 36:92-96.
49. NEDREBO BG, HOLM PI, UHLVING S et al.: Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur. J. Endocrinol. (2002) 147:583-589.
50. TENG CS, YEUNG RTT: Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study. J. Clin. Endocrinol. Metab. (1980) 50:144-147.
51. HASHIZUME K, ICHIKAWA I, SAKURAI A et al.: Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N. Engl. J. Med. (1991) 324:947-953.
52. MCIVER B, RAE P, BECKETT G et al.: Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N. Engl. J. Med. (1996) 334:220-224.
53. RITTMASTER RS, ZWICKER H, ABBOTT EC et al.: Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease. J. Clin. Endocrinol. Metab. (1996) 81:3283-3288.
54. PFEILSCHIFTER J, ZEIGLER R: Suppression of serum thyrotropin with thyroxine in patients with Graves' disease: effects on recurrence of hyperthyroidism and thyroid volume. Eur. J. Endocrinol. (1997) 136:81-86.
55. ALLANNIC H, FAUCHET R, ORGIAZZI J et al.: Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J. Clin. Endocrinol. Metab. (1990) 70:675-679.
56. GARCIA-MAYOR RVG, PARAMO C, LUNACANO R et al.: Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J. Endocrinol. Invest. (1992) 15:815-820.
57. MANUGENDRE D, GATEL A, CAMPION L et al.: Antithyroid drugs and Graves' disease: prospective randomized assessment of long-term treatment. Clin. Endocrinol. (1999) 50:127-132.
58. LIPPE BM, LANDAW EM, KAPLAN SA: Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J. Clin. Endocrinol. Metab. (1987) 64:1241-1245.
59. ABRAHAM P, AVENELL A, WATSON WA et al.: Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst. Rev. (2004) 2:CD003420.
60. SLINGERLAND DW, BURROWS BA: Long-term antithyroid treatment in hyperthyroidism. JAMA (1979) 242:2408-2410.
61. AZIZI F, ATAIE L, HEDAYATI M et al.: Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur. J. Endocrinol. (2005) 152:695-701.
62. IMSEIS RE, VANMIDDLESWORTH L, MASSIE JD et al.: Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J. Clin. Endocrinol. Metab. (1998) 83:685-687.
63. SANTOS RB, ROMALDIN JH, WARD LS: Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease. Thyroid (2004) 14:525-530.
64. COOPER DS: The side effects of antithyroid drugs. Endocrinologist (1999) 9:457-479.
65. TAJIRI J, NOGUCHI S: Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid (2004) 14:459-462.
66. PEARCE HS: Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin. Endocrinol. (2004) 61:589-594.
67. TOTH EL, MANT MJ, SHIVJI S et al.: Propylthiouracil-induced agranulocytosis: an unusual presentation and a possible mechanism. Am. J. Med. (1988) 85:725-727.
68. GURLEK A, COBAUKARA V, BAYRAKTAR M: Liver tests in hyperthyroidism: effect of antithyroid therapy. J. Clin. Gastroenterol. (1997) 24:180-183.
69. TAJIRI J, NOGUCHI S: Antithyroid drug-induced agranulocytosis: how has granulocyte colony-stimulating factor changed therapy? Thyroid (2005) 15:292-297.
70. LAIW Y-F, HUANG M-J, EAN K-D et al.: Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann. Intern. Med. (1993) 118:424-428.
71. WALL JR, FANG SL, KUROKI T et al.: In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis. J. Clin. Endocrinol. Metab. (1984) 58:868-872.
72. WILLIAMS KV, NAYAK S, BECKER D et al.: Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J. Clin. Endocrinol. Metab. (1997) 82:1727-1733.
73. RUIZ JK, ROSSI GV, VALLEJOS HA et al.: Fulminant hepatic failure associated with propylthiouracil. Ann. Pharmacother. (2003) 37:224-228.
74. RUSSO MW, GALANKO JA, SHRESTHA R et al.: Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. (2004) 10:1018-1023.
75. ARAB DM, MALATJALIAN DA, RITTMASTER RS: Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J. Clin. Endocrinol. Metab. (1995) 80:1083-1085.
76. HORTON RC, SHEPPARD MC, EMERY P: Propylthiouracil-induced systemic lupus erythematosus. Lancet (1989) 2:568.
77. GUNTON JE, STIEL J, CATERSON RJ et al.:Anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis: a case report and review of the literature. J. Clin. Endocrinol. Metab. (1999) 84:13-16.
78. MANDEL SJ, COOPER DS. The use of antithyroid drugs in pregnancy and lactation. J. Clin. Endocrinol. Metab. (2001) 86:2354-239
79. MORTIMER RH, CANNELL GR, ADDISON RS et al.: Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J. Clin. Endocrinol. Metab. (1997) 82:3099-3102.
80. MOMOTANI N, NOH JY, ISHIKAWA N et al.: Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J. Clin. Endocrinol. Metab. (1997) 82:3633-3636.
81. WING DA, MILLAR LK, KOONINGS PP et al.: A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy. Am. J. Obstet. Gynecol. (1994) 170:90-95.
82. MANDEL SJ, BRENT GA, LARSEN PR et al.: Review of antithyroid drug use during pregnancy and report of a case of aplasia cutis. Thyroid (1994) 4:129-133.
83. DI GIANANTONIO E, SCHAEFER C, MASTROACOVO PP et al.: Adverse effects of prenatal methimazole exposure. Teratology (2001) 64:262-266.
84. MOMOTANI N, ITO K, HAMADA N et al.: Maternal hyperthyroidism and congenital malformation in the offspring. Clin. Endocrinol. (1984) 20:695-700.
85. CHERON RG, KAPLAN MM, LARSEN PR et al.: Neonatal thyroid function after propylthiouracil therapy for maternal Graves' disease. N. Engl. J. Med. (1981) 304:525-528.
86. MESSER PM, HAUFFA BP, OLBRICHT T et al.: Antithyroid drug treatment of Graves' disease in pregnancy: long-term effects on somatic growth, intellectual development and thyroid function of the offspring. Acta. Endocrinol. (1990) 123:311-316.
87. EISENSTEIN Z, WEISS M, KATZ Y et al.: Intellectual capacity of subjects exposed to methimazole or propylthiouracil in utero. Eur. J. Pediatr. (1992) 151:558-559.
88. AZIZI F, KHAMSEH ME, BAHREYNIAN M et al.: Thyroid function and intellectual development of children of mothers taking methimazole during pregnancy. J. Endocrinol. Invest. (2002) 25:586-589.
89. MOMOTANI N, NOH J, OYANAGI H et al.: Antithyroid drug therapy for Graves' disease during pregnancy. Optimal regimen for fetal thyroid status. N. Engl. J. Med. (1986) 315:24-28.
90. AMINO N, MORI H, IWARANI Y et al.: High prevalence of transient post-partum thyrotoxicosis and hypothyroidism. N. Engl. J. Med. (1982) 306:849-552.
91. STAGNARO-GREEN A, ROMAN H, COBIN RH et al.: A prospective study of lymphocyte-initiated immunosuppression in normal pregnancy: evidence of a T-cell etiology for postpartum thyroid dysfunction. J. Clin. Endocrinol. Metab. (1992) 74:645-653.
92. AZIZI F, BRAVERMAN LE: Management of postpartum thyrotoxicosis. Curr. Opin. Endocrinol. Diabetes (2005) 12:471-476.
93. LAZARUS JH, LUEATE ME: Prevention and treatment of postpartum Graves' disease. Baillieres. Clin. Endocrinol. Metab. (1997) 11:549-560.
94. LOW LC, LANG J, ALEXANDER WD: Excretion of carbimazole and propylthiouracil in breast milk, Lancet (1979) 2:1011.
95. KAMPMANN JP, JOHNSEN K, HANSEN JM et al.: Propylthiouracil in human milk. Revision of a dogma. Lancet (1980) 1:736-737.
96. AZIZI F,KHOSNIAT M, BAHRAINIAN M et al.: Thyroid function and intellectual development of infants nursed by mothers taking methimazole. J. Clin. Endocrinol. Metab. (2000) 85:3233-3238.
97. AZIZI F: Effect of methimazole treatment of maternal thyrotoxicosis on thyroid function in breast-feeding infants. J. Pediatr. (1996) 128:855-858.
98. MOMOTANI N, YAMASHITA R, MAKONO F et al.: Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil. Clin. Endocrinol. (2000) 53:177-181.
99. AZIZI F, HEDAYATI M: Thyroid function in breast-fed infants whose mothers take high doses of methimazole. J. Endocrinol. Invest. (2002) 25:493-496.
100. AZIZI F, BAHRAINIAN M, KHAMSEH M et al.: Intellectual development and thyroid function in children who were breast-fed by thyrotoxic mothers taking methimazole. J. Pediatr. Endocrinol. Metab. (2003) 16:1239-1243.
101. AMERICAN ACADEMY OF PEDIATRICS COMMITTEE OF DRUGS: Transfer of drugs and other chemicals into human milk. Pediatrics (2001) 108:776-789.
102. ALLANNIC H, FAUCHET R, ORGIAZZI J et al.: Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. J. Clin. Endocrinol. Metab. (1990) 70:675-679.
103. VITTI P, RAGO T, CHIOVATO L et al.: Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid (1997) 7:369-375.
104. BECKER DV: Choice of therapy for Graves' hypetthyroidism. N. Engl. J. Med. (1984) 311:464-466.
105. WARTOFSKY L: Has the use of antithyroid drugs for Graves' disease become obsolete? Thyroid (1993) 3:335-344.
106. HOLM LE: Changing annual incidence of hypothyroidism after 131I therapy for hyperthyroidism, 1951-1975. J. Nucl. Med. (1982) 23:108-112.
107. SRIDAMA A, McCORMICK M, KAPLAN EL et al.: Long-term follow up study of compensated low dose 131I therapy. N. Engl. J. Med. (1984) 311:426-432.
108. BIONDI B, FAZIO S, CARELLA C et al.: Cardiac effects of long-term thyrotropin-suppressive therapy with levothyroxine. J. Clin. Endocrinol. Metab. (1993) 77:334-338.
109. FABER J, GALLOE AM: Changes in bone mass during prolonged subclinical hypethyroidism due to L-thyroxine treatment: A meta-analysis. Eur. J. Endocrinol. (1994) 130:350-356.
110. DONG BJ, HAUEK WW, GAMBERTOGLLO JG et al.: Bioequivalence of generie and brand-name levothyroxine products in the treatment of hypothyroidis. JAMA (1997) 277:1205-1213.
111. ROSS DS, DANIELS GH, GOUVEIA D: The use and limitations of a chemiluminescent throtropin assay as a single thyroid function test in an outpatient endocrine cline. J. Clin. Endocrinol. Metab. (1990) 71:764-769.
112. CANARIS GJ, MANOWITZ NR, MAYOR G et al.: The Colorado thyroid disease prevalence study. Arch. Intern. Med. (2000) 160:526-534.
113. AMINO N, TANIZAWA O, MORI H et al.: Aggravation of thyrotoxicosis in early pregnancy and after delivery in Graves' diseae. J. Clin. Endocrinol. Metab. (1982) 55:108.